Showing 2761-2770 of 5689 results for "".
- Ocular Therapeutix Announces Christopher White as Senior Vice President, Head of Business and Corporate Developmenthttps://modernod.com/news/ocular-therapeutix-announces-christopher-white-as-senior-vice-president-head-of-business-and-corporate-development/2476725/Ocular Therapeutix announced the appointment of Christopher White as Senior Vice President, Head of Business and Corporate Development. “We are thrilled to welcome Chris to the Ocular team to oversee business and corporate development,” Antony Mattessich, President and Chief Executive Offi
- Children’s Hospital Los Angeles Has Treated 14 Patients With Retinal Degeneration Using Gene Therapyhttps://modernod.com/news/childrens-hospital-los-angeles-has-treated-14-patients-with-retinal-degeneration-using-gene-therapy/2476727/More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at The Vision Center at Children’s Hospital Los Angeles (CHLA) have successfully completed the pr
- One Week Left to Submit Nominations for OWL Awardshttps://modernod.com/news/one-week-left-to-submit-nominations-for-owl-awards/2476721/OWL is accepting nominations for the
- UK to Test “Subscription-Style” Payment Model in Effort to Spur Development of New Antibioticshttps://modernod.com/news/uk-to-test-subscription-style-payment-model-in-effort-to-spur-development-of-new-antibiotics/2476717/The NHS will test a “subscription-style” payment model for antibiotics as part of efforts by the UK government to incentivise companies to develop new medicines to tackle drug-resistant infections. Under the proposed scheme, the Department of Health and Social Care said Tuesday that d
- Wize Pharma Enters Joint Venture With Cannabics Pharmaceuticals to Develop Cannabinoid Ophthalmic Treatmentshttps://modernod.com/news/wize-pharma-enters-joint-venture-with-cannabics-pharmaceuticals-to-develop-cannabinoid-ophthalmic-treatments/2476713/Israel-based Wize Pharma and Cannabics Pharmaceuticals have together created and adopted a business plan for a joint venture focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the joint venture was a con
- Roche, Spark Push Back Takeover Deadline in $4.3 Billion Dealhttps://modernod.com/news/roche-spark-push-back-takeover-deadline-in-4-3-billion-deal/2479565/Roche and Spark Therapeutics agreed to extend the deadline for the Swiss drugmaker’s $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains “fully committed” to a deal it sees closing this year, according to a Reuters
- Zeiss Receives FDA Clearance for Clarus 700 Ultra-Widefield Imaging Devicehttps://modernod.com/news/zeiss-receives-fda-clearance-for-clarus-700-ultra-widefield-imaging-device/2479571/Zeiss announced that it has received FDA 510(K) clearance for the Clarus 700, high-definition, ultra-widefield imaging system. Clarus 700 is the first high-resolution ultra-widefield imaging with true color and a comp
- EyePoint Pharmaceuticals Announces US Commercialization of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercialization-of-dexycu/2479573/EyePoint Pharmaceuticals announced the commercial launch of Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as
- Novartis Completes Acquisition of Xiidrahttps://modernod.com/news/novartis-completes-acquisition-of-xiidra-bolstering-ophthalmic-portfolio/2476707/Novartis announced that it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. In May, Novartis agreed to acquire Xiidr
- Ocular Therapeutix Announces Commercial Launch of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-commercial-launch-of-dextenza/2476704/Ocular Therapeutix announced the commercial launch in the United States of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of ocular inflammation and pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert that enables the delivery of drug